Capricor Therapeutics (NASDAQ:CAPR) Trading Up 4.1%

Capricor Therapeutics Inc (NASDAQ:CAPR) was up 4.1% during trading on Thursday . The stock traded as high as $17.34 and last traded at $17.20. Approximately 1,103,051 shares were traded during trading, an increase of 17% from the average daily volume of 944,693 shares. The stock had previously closed at $16.52.

Analyst Ratings Changes

Several analysts have commented on CAPR shares. Oppenheimer restated an “outperform” rating and set a $15.00 price objective on shares of Capricor Therapeutics in a research note on Monday, September 23rd. HC Wainwright restated a “buy” rating and set a $40.00 price objective on shares of Capricor Therapeutics in a research note on Tuesday, September 24th. Maxim Group lifted their price objective on shares of Capricor Therapeutics from $12.00 to $25.00 and gave the company a “buy” rating in a research note on Wednesday, September 25th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $8.00 target price on shares of Capricor Therapeutics in a report on Friday, September 20th. One investment analyst has rated the stock with a sell rating and five have given a buy rating to the company. According to data from MarketBeat.com, Capricor Therapeutics has an average rating of “Moderate Buy” and an average price target of $22.60.

Capricor Therapeutics Trading Up 3.4 %

The stock has a market capitalization of $546.20 million, a PE ratio of -20.30 and a beta of 3.92. The firm’s fifty day moving average price is $5.45 and its two-hundred day moving average price is $5.50.

Capricor Therapeutics (NASDAQ:CAPR) last announced its earnings results on Wednesday, August 7th. The biotechnology company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.03). Capricor Therapeutics had a negative net margin of 102.93% and a negative return on equity of 220.27%. The company had revenue of $3.97 million during the quarter, compared to analyst estimates of $4.51 million. As a group, sell-side analysts anticipate that Capricor Therapeutics Inc will post -1.14 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, major shareholder Shinyaku Co Ltd Nippon bought 2,798,507 shares of the firm’s stock in a transaction dated Friday, September 20th. The shares were acquired at an average price of $5.36 per share, for a total transaction of $14,999,997.52. Following the completion of the transaction, the insider now directly owns 7,090,351 shares in the company, valued at approximately $38,004,281.36. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. 12.00% of the stock is owned by company insiders.

Hedge Funds Weigh In On Capricor Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. SG Americas Securities LLC acquired a new position in shares of Capricor Therapeutics during the 3rd quarter worth approximately $133,000. Marshall Wace LLP acquired a new position in Capricor Therapeutics during the second quarter worth $426,000. Renaissance Technologies LLC grew its holdings in Capricor Therapeutics by 158.7% in the 2nd quarter. Renaissance Technologies LLC now owns 137,500 shares of the biotechnology company’s stock valued at $656,000 after buying an additional 84,350 shares in the last quarter. Main Street Financial Solutions LLC increased its stake in shares of Capricor Therapeutics by 37.5% in the 2nd quarter. Main Street Financial Solutions LLC now owns 27,500 shares of the biotechnology company’s stock worth $131,000 after acquiring an additional 7,500 shares during the last quarter. Finally, Rhumbline Advisers purchased a new position in shares of Capricor Therapeutics during the 2nd quarter worth $147,000. 21.68% of the stock is currently owned by institutional investors and hedge funds.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.